At a glance
ClinicalIndex Comparison Record- ✓Adult with locally advanced, persistent, or recurrent thyroid cancer (PTC, FTC, MTC, PDTC, or ATC)
- ✓Evidence of extrathyroidal extension and/or locally invasive disease at risk for R2 resection
- ✓At least one measurable lesion per mRECIST
- ✓Able to swallow pills
- ✕Contraindications per targeted drug instructions
- ✕Incomplete clinical data
- ✕Severe organ dysfunction, metabolic diseases, or other conditions significantly affecting survival
- ✕Other active malignant disease requiring therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06482086Phase 2RecruitingUpdate OverdueUpdated 18mo ago · Completion was 18mo agoPrecision Medicine Applied to Locally Advanced Thyroid Cancer Using Tumor-derived Organoids and In-vitro Sensitivity Testing: a Phase 2a, Single-center, Open-label, and Non-comparative Study
In Brief
A Phase 2 clinical trial evaluating Anlotinib, Lenvatinib, and 10 other interventions for Locally Advanced Thyroid Gland Carcinoma. Currently recruiting, targeting 75 participants across 1 site.
Signals
Detailed Summary
The current study aims to explore the potential advantages of anti-cancer therapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced thyroid cancer who have undergone conventional therapy in the past or unresectable patients .
Study Details
Timeline
Interventions
8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.
8/12 mg qd, po.
0.4 g bid, po.
0.3 g bid, po.
10 mg qd, po.
500 mg qd, po.
Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.
Cabozantinib 60mg qd, po.
Vandetanib 300mg qd, po.
Entrectinib 600mg qd，po.
400mg qd, po.
100mg qd，po